Selective Serotonin Reuptake Inhibitors (SSRIs) are types of antidepressants. Brand names of SSRIs include: Paxil, Zoloft, Celexa, Prozac, Lexapro, Symbyax, Wellbutrin and Effexor. These drugs inhibit neuronal serotonin and norepinephrine reuptake and slightly inhibit dopamine reuptake. SSRIs have been associated with serious, life-threatening birth defects. Research suggests that, if a mother took SSRI’s during pregnancy, [...]
SC AG Files Lawsuit Against GSK for Improper Marketing of Diabetes Drug
June 3, 2011
Drug Regulators in the US and Europe Restrict Use of Avandia (rosiglitazone)
September 23, 2010
NHTSA Raises Number of Deaths Associated with Toyota Acceleration
May 26, 2010
Toyota Pays $16.4 Million Fine
May 19, 2010
Toyota Announces Plan to Replace Accelerators in Secondary Recall
March 23, 2010
Specter Specter Evans & Manogue, P.C. Announces Filing a Class Action Lawsuit Against Oppenheimer Pennsylvania Municipal Fund
A class action lawsuit has been commenced in the United States District Court for the Western District of Pennsylvania (Case No. 2:09-cv-00514-JFC) on behalf of persons and entities that purchased shares of the Oppenheimer Pennsylvania Municipal Fund (the “Pennsylvania Fund” or “Fund”) between November 28, 2005 and November 28, 2008 (“Class Period”).
The complaint alleges that the Pennsylvania Fund, Oppenheimer Funds and certain of its officers and trustees violated the Securities Act of 1933 and the Investment Company Act of 1940 by departing from the stated investment premise and otherwise injured Fund shareholders. The complaint alleges the Pennsylvania Fund is a municipal bond fund yielding interest income exempt from federal and Pennsylvania income taxes. The complaint alleges that during the Class Period, the Registration Statements and Prospectuses misled investors about the Fund’s investment objectives, policies and the underlying risk by characterizing its investments as consistent with preservation of capital. In fact, the complaint alleges the Fund lost over 33% of its net asset value (“NAV”) in 2008 compared with an average peer group loss of approximately 9.5%. The complaint alleges that capital preservation was disregarded as the Fund significantly increased exposure through excessively risky strategies not properly disclosed to investors.
Specifically, the complaint alleges that the overarching principle of capital preservation was compromised by concentrating large positions in low rated bonds, bonds not reviewed by an independent rating agency and by portfolio concentration in high risk securities including, Tobacco Bonds, Dirt Bonds, and Inverse Floaters.
Plaintiff is seeking to recover damages on behalf of all investors in Pennsylvania Fund who purchased or held shares between November 28, 2005 and November 28, 2008. Plaintiff is represented by Specter Specter Evans & Manogue, P.C., a highly regarded Pittsburgh law firm litigating complex class action cases throughout the country.
As a member of the Class described above, you may, not later than June 29, 2009, move the Court to serve as lead plaintiff for the Class or choose to do nothing and remain an absent class member. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Your ability to share in any recovery is not, however, affected by the decision to serve as a lead plaintiff.
If you want to discuss this matter or your rights or interests, please contact us by using the form below.